Search results
Results from the WOW.Com Content Network
The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized.It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women.
Side effects of cyproterone acetate in the SExual-HOrmonal Surveillance STudy (SEHOST) Side effect Males (136 mg/day) [a] (n = 1248) (%) Females (18 mg/day) [a] (n = 1258) (%) Total (77 mg/day) [a] (n = 2506) (%) Elevated liver enzymes [b] 12.5: 3.6: 9.6 Gynecomastia, breast pain: 4.9: 1.0: 2.9 Overweightness, weight gain: 0.9: 4.1: 2.5 ...
[102] [123] Conversely, the risk of VTE in transgender women is much lower with oral or transdermal estradiol plus high-dose cyproterone acetate. [102] [123] Ethinylestradiol is thought to have been primarily responsible for the VTE risk, but cyproterone acetate may have contributed as well. [102]
Weight gain. Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. Switching to a new type of antidepressant may help reverse any weight ...
This template can be used to easily insert a table detailing the side effects of high-dose cyproterone acetate into an article. It comes with three pre-provided references. By passing the parameter |state=mw-collapsed , the table can be displayed as collapsed by default.
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now.
The risk of venous thromboembolism with EE/CPA-containing birth control pills is similar to that with EE and gestodene-, desogestrel-, and drospirenone-containing birth control pills and about 50 to 80% higher than with EE and levonorgestrel-containing birth control pills.